Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001628280-23-003182
Filing Date
2023-02-10
Accepted
2023-02-10 17:01:42
Documents
1

Document Format Files

Seq Description Document Type Size
1 SC 13G schedule13g-ajkazimi2022.htm SC 13G 73725
  Complete submission text file 0001628280-23-003182.txt   74949
Mailing Address 1207 17TH AVENUE SUITE 103 NASHVILLE TN 37212
Business Address
KAZIMI A J (Filed by) CIK: 0001075050 (see all company filings)

Type: SC 13G

Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Subject) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-85205 | Film No.: 23613159
SIC: 2834 Pharmaceutical Preparations